- Copper tripeptide serum improved hair growth: The active treatment group (copper tripeptide + Swertia japonica serum with nano-fractional radiofrequency) showed 26–50% improvement versus 0–25% in the placebo group
- Safe and well-tolerated: No serious adverse events; only one report of mild scalp itching in the active group across the entire 6-month trial
- Combined delivery approach: First study to test copper tripeptide serum delivered via nano-fractional radiofrequency for male pattern hair loss
- Pilot-scale evidence: This was a small proof-of-concept study (6 patients): the results are promising but need confirmation in larger trials
- All patients completed treatment: 100% retention across both groups over 6 months, suggesting excellent tolerability
| Study Design | Randomised, single-blind, placebo-controlled comparative study |
| Sample Size | 6 men (3 active treatment, 3 placebo) |
| Duration | 6 months with monthly sessions |
| Key Result | Active group: 26–50% improvement (Scale 1) vs placebo: 0–25% improvement (Scale 0) |
| Evidence Level | Level 4: Pilot study / case series (very small sample) |
| Author | Ruri D. Pamela |
| Journal | Journal of Clinical & Experimental Dermatology Research, Vol. 12, Article 590 |
| Published | 28 December 2021 |
| Study Type | Randomised, single-blind, placebo-controlled comparative pilot study |
| Funding | Highside Corp., Tokyo, Japan |
| Full Paper | View full text |
Why This Research Matters
Most copper peptide research has focused on GHK-Cu (glycyl-L-histidyl-L-lysine copper) in laboratory settings, studying its effects on isolated hair follicles or reviewing its gene expression profile. What has been missing is clinical research testing whether topical copper tripeptide serums actually improve hair growth in real patients.
This 2021 pilot study by Ruri D. Pamela addresses that gap. It is one of the first clinical studies to test a copper tripeptide-containing serum in men with pattern hair loss, using a proper placebo-controlled design. While the sample is small (6 patients), it represents an important step in the evidence chain: moving from laboratory proof-of-concept to human clinical testing.
The study also introduces an innovative delivery approach: using nano-fractional radiofrequency to create micro-channels in the scalp before applying the copper tripeptide serum. This builds on the same principle that makes microneedling so effective for hair growth: physical scalp stimulation combined with enhanced topical absorption produces better results than either approach alone.
What The Researchers Did
The researcher recruited 6 men aged 35–65 with moderate to severe male pattern hair loss (Hamilton-Norwood Scale IV to VI). These men were randomly assigned to one of two groups:
| Parameter | Active Group (n = 3) | Placebo Group (n = 3) |
|---|---|---|
| Device treatment | Nano-fractional radiofrequency (Venus Viva®) | Nano-fractional radiofrequency (Venus Viva®) |
| Topical application | Serum containing copper tripeptide + Swertia japonica extract | Normal saline (0.9% NaCl) |
| Session frequency | Monthly | Monthly |
| Duration | 6 months | 6 months |
| Assessment | Blinded investigator photos, patient self-assessment, trichoscopy | Same assessments |
Both groups received the same radiofrequency treatment: the only difference was what was applied to the scalp afterwards. The investigator who assessed results from photographs was blinded (did not know which group each patient was in), adding objectivity to the evaluation.
This study design gives researchers confidence that any improvement is due to the treatment, not other factors. Patients are randomly assigned to groups (randomised), the person assessing results doesn't know who got what (single-blind), and the comparison group receives a dummy treatment (placebo-controlled). This is a strong study design, though with only 6 participants, the statistical power is very limited. Think of it as a well-designed experiment that needs to be repeated on a much larger scale to confirm the findings.
What They Found
1. Investigator-assessed improvement
The investigator compared standardised photographs taken at baseline and at 6 months. The active group showed visually noticeable improvement that the blinded evaluator rated as meaningful, while the placebo group (same radiofrequency, saline instead of serum) showed minimal change.
2. Trichoscopic observations
3. Safety and tolerability
The excellent tolerability is notable. Six months of monthly radiofrequency treatments with topical serum application produced essentially no side effects, suggesting this approach is well-suited for long-term maintenance therapy.
How This Treatment Works: The Science Behind the Combination
1. Copper tripeptide: follicle stimulation and protection
Copper tripeptide (GHK-Cu) is one of the most studied peptides in regenerative medicine. Research shows it affects 31.2% of human genes, upregulating genes involved in tissue repair, collagen synthesis, and blood vessel formation while downregulating inflammatory and tissue-destructive genes. In hair specifically, the AHK-Cu study (2007) demonstrated that copper peptides promote hair follicle elongation and protect follicular cells from premature death (apoptosis).
2. Swertia japonica extract: anti-inflammatory and antioxidant support
Swertia japonica is a plant used in traditional Japanese medicine. The extract contains bioactive compounds with anti-inflammatory and antioxidant properties, which may help create a healthier scalp environment for hair growth. Scalp inflammation is increasingly recognised as a factor in androgenetic alopecia progression.
3. Nano-fractional radiofrequency: enhanced delivery and stimulation
The Venus Viva® device delivers radiofrequency energy through tiny pin-like electrodes, creating controlled micro-injuries similar to microneedling but with the added benefit of thermal energy. This serves a dual purpose: it triggers the wound healing cascade (releasing growth factors like PDGF, VEGF, and FGF) while simultaneously creating micro-channels that enhance serum absorption. This delivery principle is the same one that makes microneedling + topical combinations so effective.
Putting the Results in Context
The improvement seen in the active group (26–50% on the investigator scale) over 6 months is encouraging, but context is essential:
| Study | Treatment | Duration | Key Result |
|---|---|---|---|
| Pamela 2021 (this study) | Cu-tripeptide serum + RF | 6 months | 26–50% improvement (Scale 1) vs 0–25% placebo |
| Dhurat 2013 | Microneedling + minoxidil | 12 weeks | +91.4 hairs/cm² (82% reported >50% improvement) |
| Kuceki 2025 | MN + Cu peptides + drugs | 5–7 sessions | 26.5% TSAR improvement |
| Lee/Kim 2016 | GHK peptide + 5-ALA | 6 months | +71.5 hairs/cm² (50 mg/mL group) |
The improvement level is broadly comparable to other copper peptide studies, though direct comparison is difficult because this study used a categorical improvement scale rather than exact hair counts. The 6-month duration and monthly sessions make it a less intensive protocol than weekly microneedling regimens.
Key limitation: With only 3 patients per group, even a single unusually responsive or non-responsive patient could substantially skew the results. The findings should be interpreted as promising preliminary evidence, not definitive proof.
How This Study Fits in the Copper Peptide Evidence Base
| Study | Year | Focus | Type | Key Contribution |
|---|---|---|---|---|
| Pyo/Won et al. | 2007 | AHK-Cu peptide | Lab study | Proved copper peptides promote follicle growth and reduce cell death |
| Pickart & Margolina | 2018 | GHK-Cu review | Review | Documented 31.2% of genes affected; age-related decline |
| Lee/Kim et al. | 2016 | GHK + 5-ALA | RCT (n=45) | +71.5 hairs/cm² with GHK peptide treatment vs placebo |
| Pamela (this study) | 2021 | Cu-tripeptide + Swertia | Pilot (n=6) | First to test Cu-tripeptide serum + RF delivery clinically |
| Kuceki et al. | 2025 | Cu peptides + MN | Retrospective (n=7) | 26.5% improvement with microneedling + copper peptide combination |
This study adds a unique piece to the copper peptide puzzle: it demonstrates the concept of using energy-based devices (radiofrequency) to deliver copper peptide serums, rather than relying on simple topical application. The principle is the same as microneedling (physical scalp stimulation + enhanced ingredient absorption), but using a different technology.
| Parameter | Specification |
|---|---|
| Device | Venus Viva® nano-fractional radiofrequency |
| Active serum | Copper tripeptide + Swertia japonica extract |
| Placebo | Normal saline (0.9% NaCl) |
| Application | Serum applied immediately after radiofrequency treatment |
| Session frequency | Monthly (once per month) |
| Total duration | 6 months (6 sessions) |
| Patient population | Men aged 35–65, Hamilton-Norwood IV–VI |
| Setting | Clinical |
Note: Venus Viva® is a professional-grade device used in clinical settings. The principle of enhanced topical absorption can also be achieved through microneedling, which is more widely available. The key insight from this study is the combination approach: physical scalp stimulation followed by copper peptide serum application.
Research Limitations
- Very small sample size: With only 6 patients total (3 per group), this study has extremely limited statistical power. Results could be substantially influenced by individual variation. This is the most significant limitation
- No statistical significance testing: The paper does not report p-values or statistical tests. With n=3 per group, meaningful statistical analysis is not possible
- Categorical outcome scale: Results were reported as improvement categories (0–25%, 26–50%) rather than exact hair counts or measurements, making precise comparison with other studies difficult
- Industry funding: The study was funded by Highside Corp. (Tokyo, Japan), which may have a commercial interest in the serum product. This does not invalidate the findings but adds a potential source of bias
- Single-blind only: While the investigator assessing photos was blinded, patients knew whether they received the active serum or saline, which could influence self-reported satisfaction scores
- No long-term follow-up: The study ended at 6 months. Whether improvements are maintained after treatment cessation is unknown
- Moderate-to-severe cases only: Participants had Hamilton-Norwood IV–VI, representing more advanced hair loss. Results may differ for earlier-stage patients
- Combined treatment effect: Both groups received radiofrequency, so the study measures the added effect of the serum, not the serum alone. It cannot separate the contributions of copper tripeptide and Swertia japonica individually
What This Means for Your Hair
This pilot study adds to the growing body of evidence that combining copper peptide application with physical scalp stimulation is more effective than either approach alone. While the sample size is too small for definitive conclusions, the results are consistent with what larger studies have found:
- The Kuceki et al. 2025 study found similar improvement levels (26.5%) when combining copper peptides with microneedling
- The Dhurat 2013 landmark study established that physical scalp stimulation + topical treatment dramatically outperforms topical treatment alone
- The Gupta 2022 meta-analysis confirmed this principle across multiple pooled studies
The practical takeaway: You do not necessarily need a Venus Viva® device to benefit from this principle. The combination of microneedling (which is widely available and extensively studied) with a copper peptide serum works through the same mechanisms: creating micro-channels for enhanced absorption while triggering the body's wound healing response. The key is choosing a copper peptide formulation with proven bioactive ingredients and applying it after scalp stimulation to maximise absorption.
Key Terms Explained
- Copper Tripeptide (GHK-Cu)
- A small peptide (three amino acids: glycine, histidine, lysine) naturally bound to copper. It occurs naturally in human plasma and declines with age. Research shows it stimulates collagen production, promotes tissue repair, and activates genes involved in hair follicle growth.
- Nano-Fractional Radiofrequency
- A technology that delivers radiofrequency energy through tiny pin-like electrodes to create controlled micro-injuries in the skin. Unlike traditional microneedling (which uses physical needles), it combines mechanical disruption with thermal energy. The Venus Viva® device used in this study is one commercial system for this approach.
- Swertia japonica
- A plant from the gentian family used in traditional Japanese medicine. Its extract contains bioactive compounds with anti-inflammatory and antioxidant properties. In this study, it was combined with copper tripeptide to create the active serum formulation.
- Hamilton-Norwood Scale
- A classification system (grades I to VII) used to measure the severity of male pattern hair loss. This study included grades IV to VI, representing moderate to severe hair loss with significant crown thinning and frontal recession.
- Placebo-Controlled
- A study design where one group receives the actual treatment while another receives an inactive substitute (placebo). In this study, the placebo was normal saline (salt water) applied after the same radiofrequency procedure, allowing researchers to isolate the effect of the active serum ingredients.
- Trichoscopy
- A non-invasive diagnostic technique using a specialised microscope (dermoscope) to examine the scalp and hair at high magnification. It reveals features invisible to the naked eye, such as hair diameter variation, follicular condition, and inflammation markers.
- Perifollicular Pigmentation (Peripilar Sign)
- A brown or dark halo visible around hair follicles under trichoscopy. It indicates mild inflammation around the follicle and is commonly seen in androgenetic alopecia. Its presence or reduction can indicate treatment response.
- Single-Blind Study
- A study design where one party (typically the evaluator) does not know which treatment each participant received. In this study, the investigator assessing photographs was blinded, but patients knew whether they received the active serum or saline.
Further Reading
- The complete copper peptide science guide
- Hair mesotherapy, explained from start to finish
- Copper peptide hair serums compared (2026 guide)
For more peer-reviewed studies on hair loss and copper peptide therapy, see our full research hub.
Frequently Asked Questions
How reliable are results from a study with only 6 patients?
Very limited. A study with 6 participants (3 per group) is considered a pilot study : it demonstrates that a concept is worth investigating further, but cannot prove that a treatment works. With so few patients, one unusually responsive individual could skew the entire result. Think of it as a promising early signal, not a proven conclusion. The results become meaningful when viewed alongside larger studies on copper peptides and physical scalp stimulation that show consistent positive effects.
What is nano-fractional radiofrequency, and how is it different from microneedling?
Both create controlled micro-injuries in the scalp, but they use different mechanisms. Microneedling uses physical needles (typically 0.25–1.5 mm) to puncture the skin. Nano-fractional radiofrequency uses tiny electrodes that deliver heat energy, creating micro-injuries through thermal ablation. The end result is similar: channels for topical absorption, growth factor release, and wound healing response. Microneedling is more widely available, more extensively studied for hair loss, and can be done at home (with shorter needles). Radiofrequency devices like Venus Viva® are clinical-grade only.
Can I get the same benefit using microneedling with a copper peptide serum instead?
Likely yes. The underlying principle (physical scalp stimulation + copper peptide delivery) is the same regardless of whether you use microneedling or radiofrequency. In fact, microneedling has a larger evidence base for hair growth than radiofrequency. The Kuceki 2025 study demonstrated significant results (26.5% improvement) using microneedling combined with copper peptide serums, and the Gupta 2022 meta-analysis confirmed microneedling's efficacy across multiple studies.
What is Swertia japonica, and does it contribute to hair growth?
Swertia japonica is a plant used in traditional Japanese and Chinese medicine. The extract has documented anti-inflammatory and antioxidant properties. While there is limited research on its specific effects on hair growth, scalp inflammation is a known contributing factor in androgenetic alopecia. The anti-inflammatory properties may help create a healthier scalp environment. However, since this study combined Swertia japonica with copper tripeptide, it is impossible to determine how much each ingredient contributed independently.
Is this the same as the GHK-Cu used in other copper peptide studies?
"Copper tripeptide" and "GHK-Cu" both refer to the same molecule: glycyl-L-histidyl-L-lysine bound to a copper ion. The Pickart & Margolina 2018 review documented its extensive gene-modulating effects, and the AHK-Cu 2007 study tested a related variant on hair follicles in the lab. This study tests it in actual patients for the first time in combination with radiofrequency delivery.
Should I wait for larger studies before trying copper peptide serums?
That is a personal decision. The safety data is reassuring: copper peptides have shown excellent tolerability across all studies, with no serious adverse effects. The efficacy evidence is growing: lab studies (AHK-Cu 2007), a 45-patient RCT (Lee/Kim 2016), combination studies (Kuceki 2025), and now this pilot study all point in the same direction. Waiting for a single "definitive" large trial may mean missing years of potential benefit from an ingredient with a strong safety profile.
Why was the study funded by a company?
Industry-funded research is common in dermatology and cosmetic science. Highside Corp. (Tokyo, Japan) funded this study, which means they had a potential commercial interest in positive results. This does not automatically invalidate the findings, but it is important context. The study's single-blind design and placebo control add credibility, but the very small sample size means the results should be interpreted cautiously. Independent replication in a larger, independently funded trial would significantly strengthen the evidence.
What Hamilton-Norwood stages were included, and do results vary by severity?
Patients had Hamilton-Norwood stages IV to VI, representing moderate to severe hair loss. This is notable because more advanced hair loss is generally harder to treat (more follicles may be permanently miniaturised). The fact that improvement was observed even at these stages is encouraging. Earlier-stage patients (NW II–III) might potentially see even better results, though this has not been tested for this specific combination. The Dhurat 2013 study included NW III–IV patients and saw strong results.
Pamela RD. Evaluation Efficacy of Topically Applied Serum Containing Copper Tripeptide and Swertia Japonica Extract in Male Pattern Baldness: A Placebo-Controlled Case Study. Journal of Clinical & Experimental Dermatology Research. 2021;12:590. Available at: longdom.org.
Hairgenetix Research Hub. "Copper Tripeptide Serum for Hair Loss: A Placebo-Controlled Clinical Study (2021): A Plain-Language Summary of Pamela (2021)." Hairgenetix, 2025. Available at: https://hairgenetix.com/blogs/articles/copper-tripeptide-serum-hair-loss-clinical-study-2021
